推荐产品
生物源
rabbit
品質等級
100
500
共軛
unconjugated
抗體表格
culture supernatant
抗體產品種類
primary antibodies
無性繁殖
EP137, monoclonal
描述
For In Vitro Diagnostic Use in Select Regions
形狀
buffered aqueous solution
物種活性
human
包裝
vial of 0.1 mL concentrate (350R-24)
vial of 0.1 mL concentrate Research Use Only (350R-24-RUO)
vial of 0.5 mL concentrate (350R-25)
vial of 1.0 mL concentrate (350R-26)
vial of 1.0 mL concentrate Research Use Only (350R-26-RUO)
vial of 1.0 mL pre-dilute Research Use Only (350R-27-RUO)
vial of 1.0 mL pre-dilute ready-to-use (350R-27)
vial of 7.0 mL pre-dilute ready-to-use (350R-28)
vial of 7.0 mL pre-dilute ready-to-use Research Use Only (350R-28-RUO)
製造商／商標名
Cell Marque™
技術
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500 (concentrated)
同型
IgG
控制
lymph node, tonsil
運輸包裝
wet ice
儲存溫度
2-8°C
視覺化
nuclear
基因資訊
human ... FOXP1(27086)
一般說明
Diffuse large B-cell lymphoma (DLBCL) most likely represents different clinicopathologic entities, which are difficult to separate using standard technique. Diffuse large B-cell lymphoma (DLBCL) can be divided into the subtypes of germinal center B-cell–like (GCB), activated B-cell–like (ABC), and unclassified DLBCL. The GCB and ABC subtypes have different pathogenetic mechanisms that will impact the development of targeted therapies. Despite the robustness of gene expression profiling (GEP) in subclassifying DLBCL, GEP techniques are not applicable to the routine clinical practice due to the substantial time, technological expertise, and scarce resources required. Therefore, it is beneficial for the translational application of the GEP classification into protein expression by tumor cells to be developed through immunohistochemical (IHC) staining of formalin-fixed, paraffin-embedded tissues. Different approaches using immunophenotypic algorithms with small panels of antibody biomarkers have been developed to translate the robust information from molecular studies into a routine clinical platform, using antibodies against CD10, BCL6, MUM1/IRF4, GCET1, FoxP1, LMO2, and BCL2. Therefore, FoxP1 is useful in subclassification of DLBCL and a high cutoff (80%) for FoxP1 is needed to achieve high specificity for the ABC subtype.
品質
 IVD |  IVD |  IVD |  RUO |
聯結
FoxP1 Positive Control Slides, Product No. 350S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
外觀
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide.
準備報告
Download the IFU specific to your product lot and format
Note: This requires a keycode which can be found on your packaging or product label.
Download the latest released IFU
Note: This IFU may not apply to your specific product lot.
Note: This requires a keycode which can be found on your packaging or product label.
Download the latest released IFU
Note: This IFU may not apply to your specific product lot.
其他說明
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
法律資訊
Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany
未找到合适的产品？
试试我们的产品选型工具.
儲存類別代碼
12 - Non Combustible Liquids
水污染物質分類（WGK）
WGK 2
閃點（°F）
Not applicable
閃點（°C）
Not applicable
A A Alizadeh et al.
Nature, 403(6769), 503-511 (2000-02-17)
Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphoma, is clinically heterogeneous: 40% of patients respond well to current therapy and have prolonged survival, whereas the remainder succumb to the disease. We proposed that this variability in
J J F Muris et al.
The Journal of pathology, 208(5), 714-723 (2006-01-10)
Clinical outcome in patients with diffuse large B cell lymphomas (DLBCL) is poorly predictable. Expression of proteins related to germinal centre B (GCB) cell or activated B cells (ABC) and expression of apoptosis-regulating proteins Bcl-2 and XIAP have been found
Lluís Colomo et al.
Blood, 101(1), 78-84 (2002-10-24)
To analyze the relationship between immunophenotyping profile and main clinicopathological features and outcome in diffuse large B-cell lymphoma (DLBCL), we studied 128 patients (59 men, 69 women; median age 65 years) consecutively diagnosed with de novo DLBCL in a single
William W L Choi et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 15(17), 5494-5502 (2009-08-27)
Hans and coworkers previously developed an immunohistochemical algorithm with approximately 80% concordance with the gene expression profiling (GEP) classification of diffuse large B-cell lymphoma (DLBCL) into the germinal center B-cell-like (GCB) and activated B-cell-like (ABC) subtypes. Since then, new antibodies
Christine P Hans et al.
Blood, 103(1), 275-282 (2003-09-25)
Diffuse large B-cell lymphoma (DLBCL) can be divided into prognostically important subgroups with germinal center B-cell-like (GCB), activated B-cell-like (ABC), and type 3 gene expression profiles using a cDNA microarray. Tissue microarray (TMA) blocks were created from 152 cases of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门